Earnings Review · 06 August 2026
AstraZeneca Reported: Clears the Faith-Based Screen, With a Caveat on the Broader Standard.
The print
Revenue $15.38B. EPS $1.32 vs $1.25 expected.
Give the business its due
The business itself is genuinely strong: revenue growing about 12%, net margins near 17%, a moderate competitive moat.
The valuation lens
Our framework labels the valuation MODERATE. Fair value lands near $162 against a $186 share price, a margin of safety of about -13%. The trailing multiple sits around 27 times earnings, which only makes sense if the growth holds.
The ethical lens, our differentiator
Clears the faith-based (AAOIFI) screen and sits borderline on our broader anchor screen. Compliant with a caveat, weigh the divergence for your own conviction.
The compliant alternative
There is no direct compliant equivalent in the same industry on our screen, the honest answer is to screen a step wider rather than reach for a false substitute.
The verdict for a values-conscious investor
It clears the screen; size it to your own risk and conviction. We do not confuse a strong quarter with a suitable holding.
This is analysis, not financial advice. Always manage your risk.
